President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...